immunity News and Research

RSS

mRNA-based COVID-19 vaccination during pregnancy provides passive SARS-CoV-2 immunity to neonates 16 days after first dose

Recently, a group of researchers analyzed 122 pregnant women and their neonates at the time of birth. All the women studied received 1 or both doses of a messenger RNA (mRNA)-based vaccine for COVID-19. Of the 122 women part of the study, 55 had received only the first dose of the vaccine while 67 women had received both doses of the mRNA vaccine by the time they gave birth; 85 women had received the Pfizer-BioNTech vaccine, and 37 women received the Moderna vaccine. The study is published on the preprint server, bioRxiv.

11 Apr 2021

L452R and Y453F SARS-CoV-2 mutations increase transmission and evade immunity

Mutations from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have created multiple variants. Some variants, such as those found in South Africa and Brazil, have caused concern for their potential to evade the immune response. While vaccination efforts are underway, the world is racing against the viruses’ ability to evolve under selective pressure.

11 Apr 2021

Pregnant women transmit SARS-CoV-2 and vaccine-induced antibodies to fetus

Pregnant women are at high risk for severe COVID-19 infection and death. Yet, insufficient safety data on babies has led many guidelines to leave the decision-making and potential threats to future mothers. While the vaccine trials did not directly test pregnant women, more real-world data suggests the vaccine may provide immunity benefits to newborns through breastmilk.

11 Apr 2021

Analysis highlights the need for a more nuanced approach to COVID-19 vaccine prioritization

It's time for a more nuanced approach to vaccine prioritization, as more contagious COVID-19 variants become prevalent and a third wave of infections threatens to overwhelm hospitals in some provinces, according to an analysis published today in the Canadian Medical Association Journal.

9 Apr 2021

Researchers use genetics to identify potential drugs for early management of COVID-19

A new study using human genetics suggests researchers should prioritize clinical trials of drugs that target two proteins to manage COVID-19 in its early stages.

9 Apr 2021

Study points to the involvement of Interleukin 33 in immunity to Sars-CoV-2

Since the beginning of the coronavirus pandemic, scientists and physicians worldwide undertook enormous efforts to understand the disease caused by the virus.

9 Apr 2021

Researchers identify several novel SARS-CoV-2 inhibitors

Researchers in London, UK, have identified several compounds with SARS-CoV-2 inhibiting properties, that potentially may be developed into antiviral solutions in the future.

9 Apr 2021

Fauci thanks US health workers for sacrifices but admits PPE shortages drove up death toll

Dr. Anthony Fauci thanked America's health care workers, who "every single day put themselves at risk" during the pandemic, even as he acknowledged that PPE shortages had contributed to the deaths of more than 3,600 of them.

9 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

Serum and breast milk SARS-CoV-2 antibodies correlated in vaccinated mothers

A new study shows the correlation between serum levels of antibodies to SARS-CoV-2 and levels in breast milk following the vaccination of lactating women with a vaccine based on mRNA technology.

9 Apr 2021

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

A recent report published in the New England Journal of Medicine has revealed that the COVID-19 vaccine developed by Moderna, Inc, USA, is capable of inducing robust and durable antibody responses for at least six months post-vaccination.

8 Apr 2021

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

8 Apr 2021

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Eight months after mild COVID-19, one in ten people still has at least one moderate to severe symptom that is perceived as having a negative impact on their work, social or home life. The most common long-term symptoms are a loss of smell and taste and fatigue.

8 Apr 2021

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

Makdasi et al. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants. bioRxiv, 2021. doi: https://doi.org/10.1101/2021.04.01.438035, https://www.biorxiv.org/content/10.1101/2021.04.01.438035v2

7 Apr 2021

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

A team of scientists from the University of California Santa Cruz, USA, recently identified a novel variant (B.1.x) of SARS-CoV-2 that might be circulating in at least 20 US states and six countries globally.

7 Apr 2021

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.

7 Apr 2021

Which SARS-CoV-2 spike mutants can evade T cell immunity?

A new study reports the capability of a new variant of the virus to escape specific cellular immunity, while possessing a higher binding affinity to the host cell binding receptor, the angiotensin-converting enzyme 2 (ACE2).

7 Apr 2021

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

A new study describes the use of a single dose of vaccine based on the viral protein called the receptor-binding domain (RBD) to elicit powerful neutralizing activity against both the Wuhan strain and the most concerning VOC called the South African (SA) strain.

7 Apr 2021

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

Researchers at the Infection Biology Unit, German Primate Center, and the Georg-August-University Göttingen in Germany have found that the B.1.351 and P.1 SARS-CoV-2 variants have the potential to evade therapeutic antibodies or antibodies induced by natural infection or vaccination.

7 Apr 2021

FDA authorizes use of Symbiotica COVID-19 Self-Collected Antibody Test System

The U.S. Food and Drug Administration today announced it has issued an emergency use authorization for the Symbiotica COVID-19 Self-Collected Antibody Test System, the first antibody test authorized for use with home collected dried blood spot samples.

6 Apr 2021

immunity News and Research

mRNA-based COVID-19 vaccination during pregnancy provides passive SARS-CoV-2 immunity to neonates 16 days after first dose

L452R and Y453F SARS-CoV-2 mutations increase transmission and evade immunity

Pregnant women transmit SARS-CoV-2 and vaccine-induced antibodies to fetus

Analysis highlights the need for a more nuanced approach to COVID-19 vaccine prioritization

Researchers use genetics to identify potential drugs for early management of COVID-19

Study points to the involvement of Interleukin 33 in immunity to Sars-CoV-2

Researchers identify several novel SARS-CoV-2 inhibitors

Fauci thanks US health workers for sacrifices but admits PPE shortages drove up death toll

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

Serum and breast milk SARS-CoV-2 antibodies correlated in vaccinated mothers

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

Which SARS-CoV-2 spike mutants can evade T cell immunity?

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

FDA authorizes use of Symbiotica COVID-19 Self-Collected Antibody Test System

Industry Focus eBook - Cell biology (5th edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News